Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of MRX-4 in Healthy Volunteers
NCT03033329Phase 1Completed
- Sponsor
- MicuRx Pharmaceuticals
- Start
- Oct 2016
- Primary completion
- Mar 2018
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of contezolid acefosamil in bacterial infection (5 arms), sponsored by MicuRx Pharmaceuticals. Primary endpoint: Safety of single and multiple ascending doses of MRX-4 at Day 15. Started Oct 2016; status: completed.
02
Drugs
contezolid acefosamil
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT03033329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03033329.